FilingSEC EDGAR6-K
Tiziana Life Sciences Completes Dosing Initiation for Final Patient in Phase 2 Alzheimer's Trial
· SEC accepted
StagePhase 2
Filing content
The company has initiated dosing for the final patient in its Phase 2 clinical trial of intranasal foralumab for early/mild Alzheimer's disease, with topline data expected in Q1 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…